Table 1 Clinical characteristics of participants
|  | Test (t = 0) (n = 133) | Retest (t = 3 weeks) (n = 102) |
|---|---|---|
Gender, n (%) | Â | Â |
Male | 63 (47.4) | 46 (45.1) |
Age in years, median (range) | 52 (21–82) | 54 (21–82) |
Condition, n (%) | Â | Â |
CD | 75 (56.4) | 59 (57.8) |
UC | 53 (39.8) | 39 (38.2) |
IBD-U | 5 (3.8) | 4 (3.9) |
Disease duration in years, median (range) | 12 (1–56) | 15 (1–56) |
Method of completion, n (%) | Â | Â |
Electronically | 55 (41.4) | 44 (43.1) |
Montreal Score 1 CD – age at onset, n (%) 2 |  |  |
< 16 years | 6 (8.0) | 6 (10.2) |
17–40 years | 45 (60.0) | 32 (54.2) |
> 40 years | 24 (32.0) | 21 (35.6) |
Montreal Score 1 CD – disease location, n (%) 2 |  |  |
Ileal | 21 (28.0) | 18 (30.5) |
Colonic | 27 (36.0) | 23 (39.0) |
Ileocolonic | 27 (36.0) | 18 (30.5) |
Montreal Score 1 CD - disease behaviour, n (%) 2 | Â | Â |
Nonstricturing, nonpenetrating | 40 (53.3) | 33 (55.9) |
Stricturing | 18 (24.0) | 13 (22.0) |
Penetrating | 17 (22.7) | 13 (22.0) |
Disease extension UC/IBD-U, n (%) 3 | Â | Â |
Proctitis | 11 (19.0) | 9 (20.9) |
Left-sided (distal to splenic flexure) | 16 (27.6) | 9 (20.9) |
Extensive (proximal to splenic flexure) | 31 (53.4) | 25 (58.1) |
Disease activity, n (%) | Â | Â |
CD in remission | 55 (41.4) | 47 (46.1) |
CD active disease | 20 (15.0) | 12 (11.8) |
UC / IBD-U in remission | 48 (36.0) | 39 (38.2) |
UC / IBD-U active disease | 10 (7.5) | 4 (3.9) |